Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: The risk-benefit balancing act

Research output: Contribution to journalArticle

11 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)419-421
Number of pages3
JournalBone Marrow Transplantation
Volume45
Issue number3
DOIs
StatePublished - 2010

Fingerprint

Primary Myelofibrosis
Hematopoietic Stem Cell Transplantation
Cell Transplantation
Homologous Transplantation
Splenectomy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

@article{e62007c0d5c4426a8b71c243065ebb6f,
title = "Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: The risk-benefit balancing act",
author = "Ayalew Tefferi",
year = "2010",
doi = "10.1038/bmt.2009.193",
language = "English (US)",
volume = "45",
pages = "419--421",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis

T2 - The risk-benefit balancing act

AU - Tefferi, Ayalew

PY - 2010

Y1 - 2010

UR - http://www.scopus.com/inward/record.url?scp=77949366004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949366004&partnerID=8YFLogxK

U2 - 10.1038/bmt.2009.193

DO - 10.1038/bmt.2009.193

M3 - Article

C2 - 20216545

AN - SCOPUS:77949366004

VL - 45

SP - 419

EP - 421

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -